as simple as a vein, appears to involve several different molecular pathways. When the papers in this issue of Cell on TIE2/angiopoietin are considered together with previous reports of vascular phenotypes resulting from targeted disruption of other genes involved in vascular development, a working model of vessel assembly can be constructed. Fifty percent of TGF-␤ null mice die from a severe defect in yolk-sac vasculogenesis, thought to result from improper interactions between epithelial and mesenchymal cells (Dickson et al., 1995) . Plateletderived growth factor receptor-␤ (PDGFR-␤) and PDGF-B ligand-null mice die perinatally from hemorrhage and have no pericytes (mesangial cells) in the kidney vasculature (Levé en et al., 1994; Soriano, 1994) . Furthermore, these animals are reported to lack pericytes throughout the entire microvascular bed (C. Betzholz, submitted). In addition, a recent study reports that mice deficient for tissue factor, die in utero at day 8.5 with vascular abnormalities that appear to be due to a defect in recruitment of smooth muscle/pericytes (Carmeliet et al., 1996b) . (Because of our relative lack of knowledge about the actions of tissue factor outside of its function in coagulation, it is difficult to speculate what precise role tissue factor might play in vessel assembly.)
The paper by Suri et al. concludes that the absence of angiopoietin-1 results in vessels that "do not properly recruit supporting cells" to the vascular wall. The Vikkula paper also speculates that the activating mutation of the TIE2 receptor is somehow linked to a deficient recruitment of mesenchymal cells to the vascular wall. They propose that TIE2 receptor expression by endothelial cells regulates ligand expression by smooth muscle cells so that the activating mutation in TIE2 would lead to decreased ligand expression in mesenchymal cells and increased proliferation of the endothelium. Further- ate number of endothelial and smooth muscle cells in venous malformations." result in defects in recruitment of vascular wall cells.
Incorporating two additional pieces of information Angiopoietin-1 null mice have "a simplified and less provided by the Suri and Davis papers, we suggest a complex vasculature containing fewer branches and modified interpretation. First, because angiopoietin-1 more homogeneously-sized vessels" and reveal little evhas no mitogenic effect on endothelial cells, the putative idence of endothelial proliferation. In fact, the authors endothelial proliferation that would be necessary for enshow no change in the total number of endothelial cells dothelial cells to line a large lumen in the venous malforbetween angiopoietin-null and normal embryos, based mation, may be a downstream event. Secondly, angioon Northern analysis of PE-CAM an endothelial marker.
poietin-1 null embryos have reduced TIE2 receptor In contrast, in the human venous malformation, the abmRNA, suggesting that the receptor levels are a function normally large lumens suggest that there must have of the ligand and perhaps not the reverse as put forth been endothelial proliferation. These differences could by Vikkula et al. (See Figure 2 diagram ). be real and reflect differences in the nature of the gene In our proposed model, angiopoietin-1 produced by defects, e.g., null versus activating, or they could be mesenchymal cells activates the TIE2 receptor on endodue to the fact that one lesion (venous malformation) thelial cells, which in turn leads to the production and forms in an adult organism whereas the other (angioor release of a recruiting signal for mesenchymal cells. poietin-1 deficiency) is occurring in a developing mouse
In the case of the pericyte, most data indicate that this embryo. We suspect that the increased endothelial prorecruiting signal is PDGF-BB. But at the level of the liferation in the venous malformations is secondary to smooth muscle, this recruitment also may involve the absence of smooth muscle cells (see below).
PDGF-AA or HB-EGF (heparin-binding epidermal growth factor), another smooth muscle chemotactic factor and Even the assembly of a vascular structure seemingly have altered production of PDGF-BB or HB-EGF and/ or reduced ability to recruit smooth muscle cells or their precursors? Do endothelial cells in venous malformations express normal levels of PDGF or HB-EGF?
What do these new data teach us about the development of blood vessels? The TIE2/angiopoietin system appears to govern maturation and stabilization of blood vessels. 'Stabilization' of a blood vessel is a stage when remodeling has ceased, new branches are not developing, and luminal size is constant, save for physiological vasodilation and vasoconstriction. Thus, the identification and initial characterization of the TIE2 receptor angiopoietin-1 system, begins to elucidate mechanisms for a process which was formerly understood only at a descriptive level. These three papers signify exciting progress in vascular biology because they begin to reveal the molecular basis for vascular remodeling.
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